Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece

Reproductive factors affect breast cancer risk, but less is known of their associations with mammographic density and whether these differ by menopausal status. We report on a cross-sectional study of 1946 pre- and 3047 post-menopausal women who joined a breast screening programme in Northern Greece during 1993-1997. The odds of having a high-density Wolfe pattern (P2/DY) was inversely associated with age (P for linear trend < 0.001) in both pre- and post-menopausal women and, for post-menopausal women, with years since menopause (P < 0.001). The odds of a P2/DY pattern declined with higher parity (P < 0.001) and younger age at first pregnancy (P = 0.05) in both pre- and post-menopausal women. They also decreased with the duration of breast-feeding in pre-menopausal women (P = 0.03 in pre- and P = 0.69 in post-menopausal women; test for interaction with menopausal status: P = 0.07). Age at menarche, age at menopause and the number of miscarriages/abortions were not associated with mammographic density. Age at first pregnancy and parity were strong correlates of mammographic density in pre- and post-menopausal women while duration of breast-feeding appeared to be particularly important in pre-menopausal women. (c) 2005 Elsevier Ltd. All rights reserved

Characterising ¹⁸F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging

Background: 18F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of 18F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades. Methods: Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of 18F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters. Results: A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation. Conclusions: 18F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake. Clinical Trial Registration: NCT03036943

Characterising ¹⁸F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging

Background:&nbsp;18F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of&nbsp;18F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades. Methods:&nbsp;Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of&nbsp;18F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters. Results:&nbsp;A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation. Conclusions:&nbsp;18F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake. Clinical Trial Registration:&nbsp;NCT03036943.</p

Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.

Introduction There is variation in margin policy for breast conserving therapy (BCT) in the UK and Ireland. In response to the Society of Surgical Oncology and American Society for Radiation Oncology (SSO-ASTRO) margin consensus ('no ink on tumour' for invasive and 2 mm for ductal carcinoma in situ [DCIS]) and the Association of Breast Surgery (ABS) consensus (1 mm for invasive and DCIS), we report on current margin practice and unit infrastructure in the UK and Ireland and describe how these factors impact on re-excision rates.Methods A trainee collaborative-led multicentre prospective study was conducted in the UK and Ireland between 1st February and 31st May 2016. Data were collected on consecutive BCT patients and on local infrastructure and policies.Results A total of 79 sites participated in the data collection (75% screening units; average 372 cancers annually, range 70-900). For DCIS, 53.2% of units accept 1 mm and 38% accept 2-mm margins. For invasive disease 77.2% accept 1 mm and 13.9% accept 'no ink on tumour'. A total of 2858 patients underwent BCT with a mean re-excision rate of 17.2% across units (range 0-41%). The re-excision rate would be reduced to 15% if all units applied SSO-ASTRO guidelines and to 14.8% if all units followed ABS guidelines. Of those who required re-operation, 65% had disease present at margin.Conclusion There continues to be large variation in margin policy and re-excision rates across units. Altering margin policies to follow either SSO-ASTRO or ABS guidelines would result in a modest reduction in the national re-excision rate. Most re-excisions are for involved margins rather than close margins